カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2012/03/01 | 26,700 | 26,700 | 25,500 | 25,500 | -1,300 | -4.9% | 613 |
2012/02/29 | 28,800 | 28,800 | 26,100 | 26,800 | -1,400 | -5% | 1,059 |
2012/02/28 | 27,950 | 28,900 | 27,320 | 28,200 | -1,850 | -6.2% | 1,772 |
2012/02/27 | 25,550 | 30,050 | 25,300 | 30,050 | +5,000 | +20% | 4,269 |
2012/02/24 | 24,700 | 25,090 | 24,680 | 25,050 | +380 | +1.5% | 155 |
2012/02/23 | 25,250 | 25,250 | 24,460 | 24,670 | -30 | -0.1% | 207 |
2012/02/22 | 24,060 | 25,500 | 24,060 | 24,700 | +580 | +2.4% | 315 |
2012/02/21 | 24,200 | 24,200 | 24,020 | 24,120 | -80 | -0.3% | 60 |
2012/02/20 | 24,000 | 24,290 | 24,000 | 24,200 | +200 | +0.8% | 105 |
2012/02/17 | 24,000 | 24,190 | 23,810 | 24,000 | +20 | +0.1% | 173 |
2012/02/16 | 24,200 | 24,200 | 23,800 | 23,980 | -10 | ±0% | 139 |
2012/02/15 | 23,930 | 24,230 | 23,930 | 23,990 | -220 | -0.9% | 107 |
2012/02/14 | 23,960 | 24,450 | 23,960 | 24,210 | +240 | +1% | 104 |
2012/02/13 | 25,000 | 25,000 | 23,950 | 23,970 | -1,280 | -5.1% | 682 |
2012/02/10 | 25,010 | 25,600 | 25,010 | 25,250 | +250 | +1% | 122 |
2012/02/09 | 24,800 | 25,250 | 24,800 | 25,000 | +200 | +0.8% | 64 |
2012/02/08 | 24,750 | 25,200 | 24,710 | 24,800 | +100 | +0.4% | 89 |
2012/02/07 | 24,750 | 24,900 | 24,600 | 24,700 | -50 | -0.2% | 74 |
2012/02/06 | 24,600 | 25,290 | 24,570 | 24,750 | +190 | +0.8% | 93 |
2012/02/03 | 24,560 | 24,880 | 24,550 | 24,560 | +10 | ±0% | 82 |
2012/02/02 | 24,500 | 24,900 | 24,500 | 24,550 | +50 | +0.2% | 91 |
2012/02/01 | 24,900 | 24,900 | 24,500 | 24,500 | -400 | -1.6% | 115 |
2012/01/31 | 24,730 | 25,080 | 24,720 | 24,900 | +100 | +0.4% | 72 |
2012/01/30 | 24,510 | 25,000 | 24,500 | 24,800 | +200 | +0.8% | 86 |
2012/01/27 | 24,860 | 24,860 | 24,490 | 24,600 | -260 | -1% | 148 |
2012/01/26 | 24,580 | 24,860 | 24,550 | 24,860 | -40 | -0.2% | 112 |
2012/01/25 | 25,010 | 25,010 | 24,600 | 24,900 | -240 | -1% | 222 |
2012/01/24 | 25,000 | 25,300 | 24,700 | 25,140 | +20 | +0.1% | 61 |
2012/01/23 | 25,500 | 25,590 | 25,120 | 25,120 | +120 | +0.5% | 206 |
2012/01/20 | 24,570 | 25,000 | 24,570 | 25,000 | +280 | +1.1% | 78 |
2012/01/19 | 24,600 | 24,950 | 24,500 | 24,720 | +120 | +0.5% | 59 |
2012/01/18 | 24,310 | 25,200 | 24,200 | 24,600 | -120 | -0.5% | 139 |
2012/01/17 | 25,150 | 25,390 | 24,530 | 24,720 | -430 | -1.7% | 193 |
2012/01/16 | 25,220 | 25,500 | 25,130 | 25,150 | -450 | -1.8% | 112 |
2012/01/13 | 25,560 | 26,090 | 25,040 | 25,600 | -10 | ±0% | 352 |
2012/01/12 | 26,800 | 26,800 | 25,570 | 25,610 | -480 | -1.8% | 236 |
2012/01/11 | 26,990 | 27,280 | 26,070 | 26,090 | -120 | -0.5% | 372 |
2012/01/10 | 27,000 | 27,000 | 26,030 | 26,210 | -1,190 | -4.3% | 697 |
2012/01/06 | 27,500 | 27,700 | 26,900 | 27,400 | -370 | -1.3% | 775 |
2012/01/05 | 28,050 | 28,580 | 27,140 | 27,770 | -560 | -2% | 961 |
2012/01/04 | 28,620 | 29,360 | 27,850 | 28,330 | -1,620 | -5.4% | 2,207 |
2011/12/30 | 34,750 | 34,750 | 29,750 | 29,950 | -4,800 | -13.8% | 5,931 |
2011/12/29 | 34,750 | 34,750 | 34,700 | 34,750 | +5,000 | +16.8% | 1,712 |
2011/12/28 | 27,200 | 29,750 | 27,200 | 29,750 | +5,000 | +20.2% | 3,821 |
2011/12/27 | 24,400 | 24,750 | 23,300 | 24,750 | +90 | +0.4% | 99 |
2011/12/26 | 25,000 | 25,000 | 24,310 | 24,660 | -1,040 | -4% | 148 |
2011/12/22 | 25,300 | 25,700 | 25,210 | 25,700 | +350 | +1.4% | 88 |
2011/12/21 | 25,500 | 25,990 | 25,340 | 25,350 | -740 | -2.8% | 51 |
2011/12/20 | 25,500 | 26,100 | 25,340 | 26,090 | -310 | -1.2% | 49 |
2011/12/19 | 26,500 | 26,700 | 25,400 | 26,400 | -80 | -0.3% | 43 |
3101~
3150
件表示中 / 3571件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 30,400円 | -43.1% | - | 0.00% | - | 1.81倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
カイオム | 9,900円 | +2.6% | - | 0.00% | - | 5.73倍 |
|
独自の抗体作製技術を持つ理研発の創薬ベンチャー。医薬品候補抗体導出と技術供与が収益源 |
VIS | 91,700円 | +87.8% | +265.7% | 0.00% | 55.08倍 | 2.53倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 82,200円 | +14.5% | - | 0.00% | - | 2.43倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
カイノス | 119,200円 | +6.8% | -13.8% | 2.68% | 9.13倍 | 0.78倍 |
|
臨床検査薬の中堅メーカー。生化学、免疫血清学的検査用試薬に重点。共同開発の促進に注力 |
市場注目の銘柄
チャート関連のコラム